Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Probable ATP-dependent RNA helicase DDX53 (DDX53) is a member of the DEAD-box RNA helicase family, characterized by its ability to unwind RNA in an ATP-dependent manner. It contains several domains common to other DEAD-box proteins, is encoded by an intronless gene on the human X chromosome, and is primarily expressed in cancer cells. DDX53 has been implicated in tumorigenesis through interactions with microRNAs and histone deacetylases, and is associated with stem cell-like properties, autophagy, and resistance to anti-cancer drugs. It may serve as a biomarker for certain cancers (notably breast adenocarcinoma) and has also been linked to Autism Spectrum Disorder. The 3D molecular structure has recently been elucidated, providing a basis for structure-based drug design targeting its helicase domain for cancer therapy.
Inhibition of ATP-dependent RNA helicase activity, interference with RNA metabolic processes central to cell proliferation and survival
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Probable ATP-dependent RNA helicase DDX53 (DDX53).